Literature DB >> 7491859

Ovarian function after seven years' use of a levonorgestrel IUD.

I Barbosa1, S E Olsson, V Odlind, T Goncalves, E Coutinho.   

Abstract

Fifteen women with regular menstrual periods and seven amenorrheic women who had been using a levonorgestrel-releasing (LNg) IUD for more than seven years were studied. For controls, eight women using TCu380Ag IUDs for more than seven years were studied during two complete menstrual cycles. Ovarian function was assessed with hormonal determination and ultrasound examinations. The regularly menstruating women were studied for two complete menstrual cycles and the amenorrheic women for eight weeks. In the regularly menstruating LNg-IUD users, according to progesterone levels, 93% of the cycles were ovulatory but just 58% of these 'ovulatory' cycles showed normal follicular growth and rupture. Follicular cysts and luteinization of regressing follicles were observed in 42% of the 26 'ovulatory' cycles studied. SHBG capacity was decreased in the LNg-IUD users compared with the TCu380Ag users. Progesterone levels were lower in the LNg-IUD users compared with the TCu380Ag users but this difference was not statistically significant. Preovulatory estradiol and LH levels were lower in the LNg-IUD users than in the TCu380Ag users. These differences were not statistically significant. For the amenorrheic women, five had follicular cysts that disappeared spontaneously within 45 days. Two women showed follicular development and rupture. The presence of good cervical mucus was observed in 69% of the ovulatory cycles studied in the LNg-IUD users. This indicates that effects on cervical mucus cannot be the main mechanism of action of the LNg-IUDs. It is concluded that LNg-IUDs may exert a contraceptive effect in many different ways, such as inhibition of ovulation, endometrial changes preventing implantation, alteration of physical and chemical properties of cervical mucus affecting sperm transport and subtle disturbances in hypothalamic pituitary ovarian function, resulting in alterations of follicular development and rupture.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7491859     DOI: 10.1007/bf01987274

Source DB:  PubMed          Journal:  Adv Contracept        ISSN: 0267-4874


  7 in total

1.  Benefit-risk assessment of the levonorgestrel intrauterine system in contraception.

Authors:  Tiina Backman
Journal:  Drug Saf       Date:  2004       Impact factor: 5.606

Review 2.  Reversible contraception update: the importance of long-acting reversible contraception.

Authors:  Renee E Mestad; Jessica Kenerson; Jeffrey F Peipert
Journal:  Postgrad Med       Date:  2009-07       Impact factor: 3.840

3.  Safety, efficacy and patient acceptability of the contraceptive and non-contraceptive uses of the LNG-IUS.

Authors:  Paula H Bednarek; Jeffrey T Jensen
Journal:  Int J Womens Health       Date:  2010-08-09

4.  Is antibiotic prophylaxis mandatory after the insertion of levonorgestrel-releasing intrauterine systemin order to decrease the risk of pelvic inflammatory disease?

Authors:  O Munteanu; L Radulescu; O Bodean; C Cirstoiu; D Secara; M Cirstoiu
Journal:  J Med Life       Date:  2013-12-25

5.  Effects of the levonorgestrel-releasing intrauterine device on the immune microenvironment of the human cervix and endometrium.

Authors:  Uma Shanmugasundaram; Joan F Hilton; J William Critchfield; Ruth M Greenblatt; Linda C Giudice; Sarah Averbach; Dominika Seidman; Barbara L Shacklett; Karen Smith-McCune
Journal:  Am J Reprod Immunol       Date:  2016-08       Impact factor: 3.886

Review 6.  Steroid Hormones and Their Action in Women's Brains: The Importance of Hormonal Balance.

Authors:  Juan Pablo Del Río; María I Alliende; Natalia Molina; Felipe G Serrano; Santiago Molina; Pilar Vigil
Journal:  Front Public Health       Date:  2018-05-23

Review 7.  Special Considerations for Women of Reproductive Age on Anticoagulation.

Authors:  Tali Azenkot; Eleanor Bimla Schwarz
Journal:  J Gen Intern Med       Date:  2022-05-31       Impact factor: 6.473

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.